Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials
Dr Larry Anderson summarizes the study design and updated data of the MAIA trial, and Dr Rebecca Silbermann compares it against the SWOG 0777 trial.
EP: 1.Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM
EP: 2.Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM
EP: 3.Determining the Right Patients with NDMM for Autologous Stem Cell Transplant
EP: 4.Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM
EP: 5.Treating Patients with High-Risk NDMM
EP: 6.Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
Now Viewing
EP: 7.Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials
EP: 8.Transplant-Ineligible Multiple Myeloma: The ENDURANCE Study
EP: 9.Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM
EP: 10.Maintenance Therapy in Transplant-Ineligible NDMM
EP: 11.Available Treatment Options for Relapsed/Refractory Multiple Myeloma
EP: 12.Bispecific Antibodies in the Treatment of R/R MM
EP: 13.CAR-T Therapy in R/R MM Treatment
EP: 14.Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy
EP: 15.Sequencing Therapies in Patients with R/R MM
EP: 16.Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022
EP: 17.Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
